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Immune Activation and Suppression by Group B Streptococcus in a
Murine Model of Urinary Tract Infection
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Group B streptococcus (GBS) is a common commensal of the gastrointestinal and vaginal mucosa and a
leading cause of serious infections in newborns, the elderly, and immunocompromised populations. GBS also
causes infections of the urinary tract. However, little is known about host responses to GBS urinary tract
infection (UTI) or GBS virulence factors that participate in UTI. Here we describe a novel murine model of
GBS UTI that may explain some features of GBS urinary tract association in the human host. We observed
high titers and heightened histological signs of inflammation and leukocyte recruitment in the GBS-infected
kidney. However, extensive inflammation and leukocyte recruitment were not observed in the bladder, sug-
gesting that GBS may suppress bladder inflammation during cystitis. Acute GBS infection induced the
localized expression of proinflammatory cytokines interleukin-1 (IL-1), macrophage inflammatory pro-
tein-1 (MIP-1), MIP-1, and IL-9, as well as IL-10, more commonly considered an anti-inflammatory
cytokine. Using isogenic GBS strains with different capsule structures, we show that capsular sialic acid
residues contribute to GBS urinary tract pathogenesis, while high levels of sialic acid O-acetylation attenuate
GBS pathogenesis in the setting of UTI, particularly in direct competition experiments. In vitro studies
demonstrated that GBS sialic acids participate in the suppression of murine polymorphonuclear leukocyte
(PMN) bactericidal activities, in addition to reducing levels of IL-1, tumor necrosis factor alpha, IL-1,
MIP-1, and KC produced by PMNs. These studies define several basic molecular and cellular events
characterizing GBS UTI in an animal model, showing that GBS participates simultaneously in the activation
and suppression of host immune responses in the urinary tract.
Group B streptococcus (GBS) is the leading cause of bac-
terial sepsis and meningitis in human newborns and is increas-
ingly associated with invasive infections in adult populations
such as pregnant women, diabetics, and the elderly (11, 16, 48,
65). GBS colonizes the gastrointestinal and vaginal mucosa of
approximately 30% of individuals tested at a given time and
nearly 2/3 of those tested at multiple intervals over a year (35).
While GBS colonization occurs asymptomatically, localized in-
fections of the skin, lungs, and urinary tract are associated with
progression to serious systemic infections in individuals with a
compromised or underdeveloped immune system (4, 16, 48,
65). For example, vaginal colonization in late pregnancy is
associated with vertical transmission of GBS in utero due to
ascending amniotic infection or by aspiration of contaminated
vaginal fluids during delivery. Pneumonia, sepsis, and menin-
gitis are potential complications of GBS transmission to the
neonate, reflecting an array of bacterial virulence factors that
act to impede phagocytic clearance, resulting in host tissue
injury (10). Much of what is known about GBS virulence has
been defined in animal models of systemic infection (18, 20, 23,
25, 28, 46, 47). GBS has also been described in animal models
of localized colonization and infection, including vaginal (7, 8),
pulmonary (15, 19, 22), mammary (52), and orogastric (27)
infection models. GBS can also cause cystitis and pyelonephri-
tis (54, 55), but the urinary tract is less well characterized as a
site of GBS-host interactions.
Asymptomatic bacteriuria and urinary tract infection (UTI)
caused by GBS are common among pregnant, elderly, and
otherwise immunocompromised individuals, groups with a
higher risk of ascending pyelonephritis that can progress to
bacteremia (11, 16, 53, 55). It has been estimated that up to 7%
of pregnant women have significant titers of GBS in their urine
(36). While typically asymptomatic, GBS bacteriuria in preg-
nancy is an independent risk factor for maternal pyelonephritis
and chorioamnionitis as well as neonatal GBS disease (1, 36,
41, 42). Other studies of elderly populations with UTIs show an
involvement of GBS in as many as 39% of nursing home
residents over 70 years of age (4). This result stands in striking
contrast to the proportion of UTIs associated with GBS in
younger populations, estimated at 1 to 2% (14). Despite the
abundant molecular epidemiological data regarding GBS, little
is known about GBS UTI pathogenesis. This dearth of under-
standing contrasts dramatically to our extensive knowledge of
disease processes involving the more common etiologic agent
of UTI, uropathogenic Escherichia coli (UPEC), which suc-
cessfully utilizes multiple immune evasion strategies to persist
within the urinary tract (45, 49, 61, 62).
During systemic infection, GBS employs a number of strat-
egies to avoid recognition and clearance by the host immune
system. Capsular polysaccharide is one of the best-character-
ized GBS virulence factors. GBS capsule is critical for systemic
disease progression in animal models (60). More specifically,
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the outermost sialic acid residues of the capsule polymer,
which are identical to host surface moieties, limit complement
deposition, prevent phagocytosis, and suppress neutrophil ox-
idative burst and granule protease release (2, 6, 12, 34, 50).
Recent studies demonstrated that GBS surface sialic acids
interact with host sialic acid binding immunoglobulin-like lec-
tins (Siglecs), a family of surface receptors that are expressed
on immune cells (5). Interactions between GBS sialic acids and
human polymorphonuclear leukocyte (PMN) Siglec-9 lead to
reduced PMN bactericidal functions and limit GBS killing,
whereas modification of GBS sialic acids with high levels of
O-acetylation impairs Siglec-9 binding and neutrophil suppres-
sion (6, 57, 58).
Another important virulence factor of GBS is the -hemo-
lysin/cytolysin, a pore-forming toxin responsible for the char-
acteristic beta-hemolytic phenotype of GBS on blood agar
plates (13). Expression of -hemolysin/cytolysin is correlated
with disease severity in murine models of intranasal and intra-
venous administration, consistent with its ability to produce
injury in both red blood cells and pulmonary epithelial and
endothelial cells (33, 43, 51). Studies also demonstrate a role of
-hemolysin/cytolysin during adherence of lung epithelium
and induction of neutrophil chemoattractant cytokine interleu-
kin-8 (IL-8) (9).
In this study, we sought to develop a robust murine model to
more fully characterize infection dynamics and host response
to GBS in the urinary tract. Here we elucidate several funda-
mental aspects of GBS-induced soluble and cellular inflamma-
tion in the murine bladder and kidney and define GBS capsule
sialic acid (but not -hemolysin/cytolysin) to be an important
determinant for host association in the urinary tract.
MATERIALS AND METHODS
Ethics statement. All animal studies were performed in accordance with ap-
provals from the Committee for Animal Studies at Washington University
School of Medicine.
Bacterial strains and growth conditions. Uropathogenic E. coli strain UTI89
(37) or UTI89::HKGFPkanr (63) was inoculated from single colonies grown on
LB agar into Luria broth containing kanamycin at 25 g/ml where appropriate
and grown statically overnight (18 to 24 h) at 37°C. Similarly, the well-charac-
terized Streptococcus agalactiae strain COH1 or clinical strains provided by Walt
Stamm (University of Washington) and Thomas Hooten (University of Florida)
were inoculated from single colonies grown on Todd-Hewitt (TH) agar into TH
broth (Difco) with antibiotics where appropriate and grown statically overnight
(18 to 24 h) at 37°C. For GBS, bacteria were diluted and grown to log phase
(optical density at 600 nm, 0.4) just prior to infection. Evaluation of GBS
virulence factors important for urinary tract pathogenesis was carried out using
previously published strains. Genetic manipulation of neuA, a bifunctional O-
acetylesterase/sialic acid synthetase, was utilized for isogenic variation of capsu-
lar structure as previously described (29, 30). Specifically, GBS strains lacking a
chromosomal copy of neuA (neuA/perm) accumulate intracellular O-acetylated
sialic acids and do not express capsule sialic acids (asialo). GBS strains that
overexpress wild-type NeuA (neuA/pneuA or COH1 wild type/pneuA) express
indistinguishable levels of sialic acids with minimal O-acetylation (GBS-loOAc),
whereas a point mutation in NeuA leads to hyper-O-acetylation of sialic acids
(neuA/pneuA301; GBS-hiOAc). These strains have been extensively character-
ized (29, 30, 57, 58). The acapsular GBS strain was previously described and
compared in our experiments to the parent wild-type strain (64). The cylE
mutant was constructed in the highly hemolytic NCTC 10/84 strain background
and was kindly provided by Victor Nizet (9).
Murine infections. Bacterial cultures, grown as described above, were col-
lected by centrifugation and resuspended in phosphate-buffered saline (PBS).
Female wild-type mice 7 to 8 weeks of age were obtained from Harlan (C3H/
HeN). Mice were anesthetized by inhalation of 3% isoflurane and inoculated
transurethrally with 1  107 CFU in 50 l (16, 29). At indicated time points,
mice were euthanized and bladders and kidneys were aseptically removed. The
number of bacteria present in the tissues was determined by homogenization of
bladders or kidney pairs in PBS and plating of serial dilutions on TH agar (for
GBS) or LB agar (for UPEC) supplemented with antibiotics when appropriate.
For competition experiments, GBS mutants were coinoculated at equal doses of
107 CFU per strain, followed by organ CFU enumeration on TH agar supple-
mented with appropriate antibiotics. Statistical analyses were performed using
the Mann-Whitney U test with Prism software (version 5.00 for Windows;
GraphPad Software). Recovered titers of zero were set to the limit of detection
of the assay.
Histological and microscopic analyses. At 24 h after inoculation with either
GBS or PBS (mock infection), animals were euthanized and bladders and kid-
neys were fixed in 10% neutral buffered formalin, embedded in paraffin, cut in
5-m-thick sections, and stained with hematoxylin and eosin (H&E) for histo-
logical analysis.
Cytokine measurement. GBS or PBS was inoculated into mouse bladders, and
organs were homogenized in 1 ml PBS at the indicated time points postinfection.
Homogenates were spun at 14,000 rpm and 4°C for 5 min, and supernatants were
frozen at 80°C until the time of the assay. Serum was obtained by submandib-
ular bleeding, and blood was placed into BD Microtainer serum separator tubes.
Following centrifugation at 14,000 rpm for 5 min, serum was frozen at 20°C
until the time of cytokine assay. Cytokine expression in serum and organ super-
natants was measured using a Bio-Plex multiplex cytokine bead kit (Bio-Rad),
which measures protein levels of 23 different proinflammatory cytokines and
chemokines. Statistical analyses were performed using the 1-sample t test
(GraphPad Prism).
Peritoneal PMN elicitation and killing assays. Murine peritoneal neutrophils
(PMNs) were elicited by intraperitoneal injection of 2 ml of thioglycolate solu-
tion (BBL), followed by cervical dislocation and extraction of the peritoneal
exudates with Hank’s balanced salt solution without Ca2, Mg2, or phenol red
(HBSS; Sigma) 4 to 6 h later for oxidative burst assessment (below) or RPMI
(Gibco)–10% heat-inactivated fetal calf serum for killing assays. PMNs (5 105)
were plated in sterile 24-well tissue culture-treated plates, GBS was added to
each well at a multiplicity of infection (MOI) of 10 to 20 in at least 3 replicate
wells per experiment, and the plate was centrifuged at 400  g for 5 min at 10°C.
Cells were then incubated at 37°C for 30 min and lysed in 0.05% Triton X-100 in
PBS, prior to serial dilution and bacterial enumeration. The number of viable
CFU was determined as the percentage of the input number of CFU, with
subsequent normalization to the percent killing of wild-type bacteria to correct
for biological variability in the degree of killing between experiments. For cyto-
kine analysis following bacterial stimulation of PMNs (at an MOI of approxi-
mately 10:1 bacteria/PMNs), cell-free culture supernatants were collected after
60 min of incubation with live GBS or 180 min of incubation with heat-killed
GBS and assessed for PMN cytokine expression relative to that of PBS-treated
PMNs using the Bio-Plex assay described above.
Oxidative burst assessment. PMN suspensions from five mice were pooled,
and cell numbers were adjusted to 500,000 cells/ml. The cells were centrifuged at
1,000  g and 4°C for 5 min, the supernatant was aspirated, and the cells were
gently resuspended in cold burst assay buffer: HBSS supplemented with 2 mM
CaCl2 and 1 mM luminol sodium salt from a freshly prepared 100 mM stock.
PMNs were kept on ice until initiation of the assay. In each well of a sterile
96-well plate (Costar 3903), 50 l of GBS suspended in Dulbecco’s PBS buffer
was combined with 100 l of PMNs (50,000 cells) in burst assay buffer at
multiplicities of infection ranging from 0.2 to 200. The plate was then sealed with
optically clear film, and luminescence was measured every 3 min with incubation
at 37°C and gentle shaking prior to each reading.
RESULTS
The murine model of GBS UTI. GBS serotypes Ia, III, and
V are most prevalent among human UTIs caused by GBS (55).
Among these, serotype III appears to have a unique predilec-
tion for causing symptomatic compared to asymptomatic UTI
(55). Here we establish a urinary tract infection model using
the well-studied serotype III strain COH1. After transurethral
inoculation of young (7- to 8-week-old) female C3H/HeN mice
with a single instilment of GBS strain COH1, we observed
low-level bladder GBS colonization in organ homogenates that
peaked at 3 h postinfection (hpi) and gradually diminished
thereafter (Fig. 1A). The numbers of CFU recovered from
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kidney homogenates were highest at 24 hpi and were signifi-
cantly higher than the numbers of CFU recovered from the
bladders at 1, 3, and 7 days postinfection (dpi) (Fig. 1B). As a
comparison, inoculation of mice with UPEC strain UTI89 re-
sulted in significantly higher bladder titers than inoculation of
mice with GBS, while GBS and UPEC colonized the kidney
equally at 24 hpi (Fig. 1C). A minimally passaged clinical
isolate of GBS, isolated from a human UTI, also demonstrated
significant kidney tropism (data not shown), similar to other
major Gram-positive uropathogens, Staphylococcus saprophyti-
cus and Enterococcus faecalis (24, 26).
Innate immune response to GBS UTI. To assess the host
factors that contribute to GBS UTI, the profiles of 23 different
cytokines and chemokines were examined in bladder homog-
enates of mice at 24 hpi. GBS infection resulted in induction of
IL-1, macrophage inflammatory protein-1 (MIP-1), MIP-
1, IL-9, and IL-10 compared to PBS mock-infected bladders
(Fig. 2A). At 24 hpi, the serum cytokines induced in the same
animals during GBS infection included KC, RANTES, and
IL-12p40 (Fig. 2B). In addition, IL-1 and MIP-1 were in-
duced 15- and 3-fold (P 	 0.10), respectively. These observa-
tions together represent a host response to GBS UTI consist-
ing of cytokines and chemokines that are primarily secreted by
monocytes and/or epithelial cells and that serve to attract and
activate PMNs.
Next, organ histology was examined at 3 h and 24 h after
infection. H&E staining of GBS-infected kidneys, which have
higher numbers of bacterial CFU than the bladder (Fig. 1),
displays large collections of immune cells in the renal pelvis
and at focal sites at 3 and 24 hpi (Fig. 3A to C), with both
organs containing bacteria and immune cells with morphology
indicative of PMNs, monocytes, and lymphocytes (Fig. 3E to
G). No inflammation was observed in PBS-treated kidneys
(Fig. 3D). In contrast, GBS-infected bladders revealed mini-
mal visible inflammatory infiltrate at the time points examined
(Fig. 3H to J), similar to PBS-treated bladders (Fig. 3K). Given
the composition of bladder cytokines, it is likely that PMNs are
also present in the bladder but are not detectable by gross
histology. Similarly, low and dispersed bacterial titers in the
bladder at this time point were difficult to detect by H&E
staining, even though they were quantifiable by CFU analysis.
GBS glycan mimicry limits murine PMN oxidative burst
and bactericidal activity. We have previously characterized a
naturally occurring GBS capsule modification (sialic acid O-
acetylation), which is expressed at low to moderate levels in all
tested serotypes (30, 58). Site-specific mutation of a GBS
FIG. 1. GBS preferentially colonizes the murine kidney. Young C3H/HeN female mice (7 to 8 weeks old) were transurethrally inoculated with
107 CFU GBS or UPEC in 50 l, and the CFU in the bladder (A) or kidney (B) was enumerated at the indicated time points. The numbers of
GBS or UPEC CFU were directly compared at 24 hpi (C). Results represent a compilation of 1 to 2 experiments (A and B) and a compilation
of 4 experiments (C), using at least 5 mice per time point. The limit of detection of the assay is indicated by a dashed line. Statistical significance
was determined by a two-tailed Mann-Whitney U test: *, P 	 0.05; **, P 	 0.01; n.s., not significant. Statistical significance shown in panel B
denotes comparison to the numbers of bladder CFU at the same time point.
FIG. 2. Cytokine/chemokine induction in the bladder and serum of GBS-infected mice. At 24 hpi, the bladders from C3H/HeN mice infected
transurethrally with GBS or mock infected with PBS were removed and homogenized (A) or the serum was collected (B), and cytokine expression
was assessed. The data are a composite of 2 separate experiments consisting of 4 to 5 mice each and are calculated as fold change compared to
the results for PBS mock-infected animals. Dark gray bars and asterisks indicate values significantly different from those for mice mock infected
with PBS (P 	 0.05), as determined by a 1-sample t test; light gray bars, P 	 0.10; dotted lines, 2-fold induction cutoff.
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O-acetylesterase has facilitated genetic control of O-acety-
lation levels (here referred to as GBS-hiOAc [80% of total
surface sialic acids modified] and GBS-loOAc [2% of total
surface sialic acids modified]) (29). Previous studies have
shown that O-acetylation does not impact GBS complement
evasion but does impede sialic acid–Siglec-9 engagement
and thus attenuates bacterial evasion of human neutrophils
(57, 58). Murine neutrophils express a homolog of human
Siglec-9 called Siglec-E. However, it is not known whether
GBS can evade murine neutrophils by sialic acid-dependent
processes.
Therefore, we investigated the hypothesis that the GBS
sialic acid capsule facilitates the evasion of murine neutrophil
killing in early stages of UTI as part of a mechanism to persist
in the murine urinary tract. We hypothesized that GBS-loOAc
would better mimic the host sialic acid structure (Fig. 4A) and
promote PMN suppression and bacterial survival than GBS-
hiOAc. To test this hypothesis in vitro, GBS-loOAc and GBS-
hiOAc were incubated with murine peritoneal PMNs for 30
min, and the surviving bacteria were enumerated. GBS-loOAc
survived significantly better than GBS-hiOAc in four indepen-
dent experiments (Fig. 4B). As a control, we show that bacteria
lacking capsular sialic acids are also killed significantly better
by murine PMNs than GBS-loOAc. In contrast, GBS-hiOAc
and GBS-asialo were killed similarly by murine PMNs. Con-
sistent with previous studies with peripheral human leukocytes
(59), we show that GBS lacking capsule is killed significantly
more readily by murine PMNs than its isogenic wild-type par-
ent strain (data not shown). In addition, we measured the
oxidative burst of isolated murine PMNs using kinetic luminol
detection of the reactive oxygen species released following
pathogen exposure. This analysis revealed that PMNs were
significantly more activated in the presence of GBS-hiOAc
than in the presence of GBS-loOAc (Fig. 4C and D).
FIG. 3. Robust inflammation in the kidney of GBS-infected animals. Hematoxylin-eosin staining of GBS-infected C3H/HeN murine kidneys
(A to G) or bladders (H to K) at 3 hpi (A B, E, F, and H) or 24 hpi (C, G, I, and J). PBS mock-infected kidney (D) and bladder (K) at 24 hpi
are shown. Representative images are shown at magnifications of 10 (A to D, K), 40 (I and J), 60 (F to H), and 100 (E). (E to G) Boxed
areas from panels A to C, respectively.
VOL. 79, 2011 GBS URINARY TRACT INFECTION 3591
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GBS capsule sialic acids suppress PMN proinflammatory
cytokine induction. We hypothesized that the observed sup-
pression of bactericidal activity by GBS sialic acids may also be
accompanied by a suppression of PMN cytokine responses.
Consistent with the in vitro data showing suppression of PMNs
in the presence of GBS-loOAc compared to the level of PMN
induction in the presence of GBS-hiOAc (Fig. 4B and D), we
observed reduced PMN production of the proinflammatory
cytokines IL-1, tumor necrosis factor alpha (TNF-), IL-1,
MIP-1, and KC upon exposure to GBS-loOAc compared to
that upon exposure to GBS-hiOAc (Fig. 5). After short-term
exposures of PMNs to live bacteria (60 min), GBS-loOAc
induced significantly lower levels of IL-1 and TNF- than
GBS-hiOAc (Fig. 5A). To better define the impact of GBS
sialic acid structure on cytokine levels at later time points,
heat-killed GBS was used to stimulate PMNs for 180 min,
followed by cytokine measurement (Fig. 5B). Heat-killed bac-
teria were used to eliminate the confounding effects of differ-
ential bacterial survival in the presence of PMNs over time. At
the later time point, there were significantly reduced levels of
IL-1, MIP-1, and KC induced by GBS-loOAc compared to
those induced by GBS-hiOAc. Thus, in vitro experiments dem-
onstrate that GBS is able to suppress murine PMN cytokine
responses in a sialic acid-dependent fashion that is impaired by
sialic acid O-acetylation.
GBS capsule sialic acids impair bladder virulence and are
disarmed by O-acetylation. To directly test whether GBS cap-
sular sialic acids contribute to pathogenesis in the urinary tract,
we infected mice with GBS-loOAc and GBS-hiOAc and com-
pared the disease outcome to that in mice infected with GBS
expressing no sialic acid residues. Consistent with the in vitro
data, strains expressing high levels of O-acetylation or lacking
sialic acid residues displayed significantly reduced numbers of
CFU in the murine bladder at 24 hpi compared to GBS-loOAc
(Fig. 6A). In fact, GBS with high levels of sialic acid O-acety-
lation did no better in the bladder than GBS lacking sialic
acids. Interestingly, very few (2/21) of the animals infected with
GBS-loOAc had completely cleared the infection by 24 h,
whereas over one-third (9/26) of the animals infected with
GBS-hiOAc had sterile bladders at this time point (Fig. 6A).
The GBS sialic acid structure did not appear to alter the
outcome of infection in the kidney at the 24-h time point (Fig.
6B). This was somewhat surprising, since both PMNs and
monocytic cellular infiltrates were seen in the kidney in re-
sponse to GBS infection (Fig. 3). Thus, further evaluation of
GBS titers at 72 hpi were performed and showed a moderate
but statistically significant reduction in GBS-hiOAc titers in
the kidney compared to the GBS-loOAc strain titers (data not
shown). More strikingly, competition studies showed a rapid
and complete exclusion of GBS-hiOAc in the presence of
GBS-loOAc in both the bladder and kidney in all animals
coinfected with both strains (Fig. 6C). In contrast to the ap-
parent role of sialic acid structure in GBS UTI pathogenesis,
investigation of the GBS -hemolysin/cytolysin encoded by
cylE, which is important for virulence in virtually all other
animal infection models (9, 19, 31, 44), showed no significant
differences in acute bladder or kidney UTI compared to the
isogenic wild-type strain (data not shown).
DISCUSSION
Urinary tract infections are among the most common bac-
terial infections in humans. UTI ranges from asymptomatic
bacteria in the urine to a painful infection of the bladder
(cystitis) or kidney (pyelonephritis) and can also progress to
infection of the blood in susceptible individuals. UPEC is the
most common cause of UTIs. However, both the incidence of
UTI and the profile of etiologic agents responsible for UTIs
differ across the age spectrum. For example, whereas GBS
FIG. 4. Unmodified capsular sialic acids of GBS suppress oxidative
burst and bactericidal activity of murine neutrophils. (A) Biochemical
similarity of the surfaces of the bladder and GBS is shown by high-
pressure liquid chromatography analysis of sialic acids from uninfected
murine bladder and GBS strains used in this study. The latter have
been previously published and are shown here for comparison. The
most common sialic acid in mammals is N-acetylneuraminic acid
(Neu5Ac). O-acetylation of Neu5Ac occurs at the carbon 7 and 9
positions of the sialic acid molecule (Neu5,7Ac2 and Neu5,9Ac2, re-
spectively). (B) GBS was incubated with murine peritoneal PMNs at
an MOI of 10 to 20:1 bacteria/PMNs, and bacterial survival was as-
sessed after 30 min. Data shown are the compilation of 4 separate
experiments. Kinetic measurement (C) and maximal luminescence
measurement (D) of in vitro oxidative burst of murine peritoneal
PMNs were assessed after incubation with GBS-hiOAc or GBS-
loOAc. The MOI was 20:1 bacteria/PMNs. Similar results were ob-
tained at an MOI of 200:1. Significant differences were determined by
the paired t test: , P 	 0.05; , P 	 0.01.
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causes only 1% of UTIs in young healthy individuals, it
causes nearly 40% of infections in elderly populations, where it
is also strongly associated with both pyelonephritis and inva-
sive infections (38, 53, 55). GBS cystitis and asymptomatic
bacteriuria are also more prevalent during pregnancy and are
independent risk factors for pyelonephritis, chorioamnionitis,
and preterm labor (56). The basis for such a diverse spectrum
of disease states is not well understood.
A robust animal model is required to elucidate host and
bacterial factors that contribute to GBS asymptomatic urinary
tract colonization and UTI pathogenesis. It is known that dif-
ferent mouse backgrounds are differentially susceptible to
UTIs with UPEC (21). For example, the C57BL/6 mouse strain
displays rapid uroepithelial exfoliation and is susceptible to
quiescent intracellular reservoir formation in response to
UPEC infection (39, 40). Alternatively, the C3H/HeN mouse
strain is susceptible to both acute and chronic active cystitis in
response to UPEC inoculation (17). A recent study described
a murine model of GBS UTI using an inoculum of 109 CFU
instilled transurethrally into C57BL/6 mice (54). In the current
study, we use a much lower dose of 107 CFU GBS in the mouse
strain C3H/HeN.
Using this model, we have found that GBS is significantly
better able to cause disease in the kidney than in the bladder,
a feature shared with the Gram-positive uropathogens E.
faecalis and S. saprophyticus (24, 26). The cytokine profile ob-
served in GBS UTIs is unique compared to that observed in
UTIs caused by other uropathogens. However, not surpris-
ingly, the overall host cytokine response to GBS is more similar
to responses seen in catheter-associated Enterococcus faecalis
UTI than UPEC UTI (17, 19). GBS infection of the murine
kidney results in an immune response characterized by innate
cellular recruitment. The proinflammatory response in the uri-
nary bladder included IL-1, which is produced by epithelial
cells as well as macrophages and other leukocytes, and is con-
sistent with an earlier study showing strong induction of this
cytokine upon GBS urinary tract infection (54). The soluble
response to GBS infection in the bladder also included the
monocyte/macrophage chemokines MIP-1 and MIP-1. The
significant induction of macrophage-associated cytokines and
chemokines produced in response to GBS infection in the
absence of a significant macrophage infiltrate into the infected
bladder suggests that resident macrophages may be activated
during infection. The presence of PMN migration and matu-
ration signals such as IL-1 and MIP1-/, along with KC, in
the serum is also consistent with a role for a PMN response to
the GBS-infected bladder.
Taken together, the data suggest that during UTI, GBS
triggers proinflammatory signals while simultaneously sup-
pressing immune responses. Past in vitro studies have shown
that serotype III GBS can directly dampen the host bacteri-
cidal response by engaging Siglecs on human PMNs via cap-
sular sialic acids (6). The experiments presented here show
that the sialic acid-containing capsular polysaccharide of sero-
type III GBS can also modulate the function of murine PMNs
to dampen bactericidal capacity and cytokine responses and
FIG. 5. GBS capsular sialic acid modification alters PMN cytokine production. Murine PMN culture supernatants were collected after 60 min
of incubation with live GBS or PBS (A) or 180 min of incubation with heat-killed GBS or PBS (B) and assayed for cytokine production. Data are
represented as fold change compared to the results for PBS-treated PMN at the same time point (n 
 3). Significant differences between
GBS-hiOAc or GBS-loOAc infection were measured by the unpaired t test: *, P	 0.05; **, P	 0.01. Each panel and statistical evaluation includes
data from at least 3 independent experiments.
FIG. 6. GBS capsular sialic acid O-acetylation limits virulence in the bladder. C3H/HeN mice were infected with isogenic GBS bearing surface
structural alterations of the capsular polysaccharide. The numbers of CFU in bladder (A) and kidney (B) were enumerated at 24 hpi (n 
 3 to
5 experiments with at least 5 mice per group). The limit of detection of the assay is indicated by a dashed line, and statistical analysis was performed
as described in the legend to Fig. 1. (C) Competition experiments were performed by coinoculation of 107 each of GBS-hiOAC and GBS-loOAc
containing different antibiotic resistance markers, followed by bacterial enumeration at 24 hpi.
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enhance bacterial virulence during a localized murine urinary
tract infection. Our finding of increased IL-10 levels in a GBS-
infected bladder is consistent with earlier findings showing
GBS-specific upregulation of IL-10 in other infection models
(6, 32). This is potentially relevant to GBS-dependent immune
suppression since IL-10 has been described to be a cytokine
able to control the degree and duration of an inflammatory
response. It is able to simultaneously dampen inflammation by
blocking the expression of proinflammatory cytokines while
also promoting the expression of anti-inflammatory molecules
(3). Interestingly, GBS is the first example of a uropathogen
that stimulates production of IL-10 in the urinary tract. Taken
together, these observations suggest that GBS acts through
multiple mechanisms to suppress immune processes during
urinary tract infection.
While GBS causes both cystitis and pyelonephritis in hu-
mans, it is difficult to know the nidus of infection on the basis
of clinical symptoms alone. For example, it cannot be ruled out
that the clinical presentation of GBS infection in the kidney
might present as cystitis or that the kidney itself could be a
reservoir of asymptomatic GBS colonization. Here we demon-
strate a tropism of GBS for the murine kidney, a finding that
may be relevant to human UTI. Taken together, the apparently
mild inflammatory response initiated by GBS in the bladder,
tropism of GBS for the kidney, and sialic acid-mediated GBS
immune evasion in the bladder show that GBS has multiple
overlapping strategies for persistence in the urinary tract.
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